Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.54 - $1.67 $2,916 - $9,018
-5,400 Reduced 43.55%
7,000 $3,000
Q1 2024

May 15, 2024

SELL
$1.3 - $2.15 $15,600 - $25,800
-12,000 Reduced 49.18%
12,400 $21,000
Q4 2023

Feb 14, 2024

SELL
$1.4 - $2.46 $3,639 - $6,396
-2,600 Reduced 9.63%
24,400 $47,000
Q3 2023

Nov 14, 2023

SELL
$2.31 - $4.18 $16,401 - $29,677
-7,100 Reduced 20.82%
27,000 $62,000
Q2 2023

Aug 14, 2023

SELL
$4.26 - $6.92 $25,560 - $41,520
-6,000 Reduced 14.96%
34,100 $145,000
Q1 2023

May 15, 2023

SELL
$5.65 - $7.56 $32,770 - $43,848
-5,800 Reduced 12.64%
40,100 $270,000
Q4 2022

Feb 14, 2023

SELL
$5.47 - $7.9 $129,092 - $186,440
-23,600 Reduced 33.96%
45,900 $297,000
Q3 2022

Nov 14, 2022

SELL
$7.42 - $11.39 $108,332 - $166,294
-14,600 Reduced 17.36%
69,500 $517,000

Others Institutions Holding XAIR

About Beyond Air, Inc.


  • Ticker XAIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 29,888,000
  • Market Cap $14M
  • Description
  • Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment ...
More about XAIR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.